Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.65
67.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Chongqing Zhifei Biological Products Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Total Current Assets
Chongqing Zhifei Biological Products Co Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Current Assets
¥46.8B
|
CAGR 3-Years
29%
|
CAGR 5-Years
41%
|
CAGR 10-Years
40%
|
|
|
Beigene Ltd
HKEX:6160
|
Total Current Assets
¥29.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Current Assets
¥3.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Current Assets
¥10.3B
|
CAGR 3-Years
73%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Current Assets
¥8.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Current Assets
¥4.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
Glance View
Chongqing Zhifei Biological Products Co., Ltd., founded in 1992, has swiftly ascended to become a key player in the Chinese biopharmaceutical landscape, primarily focusing on the development, manufacturing, and commercialization of vaccines and diagnostic products. The company operates with a vision to address pressing public health challenges, and it has established an impressive portfolio that includes vaccines for diseases like hepatitis, influenza, and COVID-19. With a robust research and development (R&D) foundation, Zhifei has secured multiple partnerships and collaborations, further bolstering its innovation pipeline and expanding its market reach. This strategic positioning within China's burgeoning biopharmaceutical sector highlights the company’s commitment to quality and safety, aligning closely with the growing national emphasis on health and disease prevention. For investors, Zhifei represents not just a stake in a successful vaccine manufacturer, but also an opportunity to participate in a transformative phase of public health management in China and beyond. The company’s recent advancements in vaccine technology and its ability to rapidly pivot in response to global health emergencies—exemplified by its expedited COVID-19 vaccine development—underscore its agility and competitive edge in a high-growth market. As the demand for advanced biological products continues to rise globally, Zhifei’s solid financial foundations, coupled with government support for the biopharmaceutical industry, position it as a compelling investment with the potential for substantial long-term returns. The confluence of innovation, strong governmental backing, and a commitment to improving public health makes Chongqing Zhifei a noteworthy candidate for investors looking to tap into the evolving healthcare landscape.
See Also
What is Chongqing Zhifei Biological Products Co Ltd's Total Current Assets?
Total Current Assets
46.8B
CNY
Based on the financial report for Sep 30, 2024, Chongqing Zhifei Biological Products Co Ltd's Total Current Assets amounts to 46.8B CNY.
What is Chongqing Zhifei Biological Products Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
40%
Over the last year, the Total Current Assets growth was 11%. The average annual Total Current Assets growth rates for Chongqing Zhifei Biological Products Co Ltd have been 29% over the past three years , 41% over the past five years , and 40% over the past ten years .
You don't have any saved screeners yet
